| 1 |
Partly verified |
Full text not readStored summary read |
N01 · Comparative efficacyAre the original subclaim and grade distinguished from the parent judgment context?Required |
The selected claim is noninferior 90-day surgical-site infection, with subclaim grade C and a note that the prespecified 10%p margin was met. The parent verdict is C, 56 points, Caution. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Absent subclaim score, status and axes are not filled with parent values. This production does not establish a new verdict or grade certification. |
Separate records of the selected subclaim, grade and note, and the original parent verdict |
Link additional materials separately to the relevant subclaim and parent context. |
| 2 |
Partly verified |
Full text not readStored summary read |
N02 · Comparative efficacyWhat surgery, population and center were actually studied?Required |
PAPRAC included patients undergoing open cystectomy and urinary diversion at a single Swiss center. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The preserved summary lacks detailed tables of age, eligibility exclusions, baseline risk and surgical details. Results are not automatically extended to robotic surgery or other populations. |
Eligibility, surgery type, urinary diversion, baseline characteristics and denominators |
Obtain the original eligibility, baseline characteristics, surgery, center and denominator records. |
| 3 |
Partly verified |
Full text not readStored summary read |
N03 · Comparative efficacyWhat were the historical intervention and comparator exposure until catheter and stent removal?Required |
The original study conditions were stopping prophylactic antibiotics 24 hours after surgery in the short arm and continuing until catheter and stent removal in the extended arm. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. No individual antibiotic type, duration, use or stopping recommendation is made. Details of exact drug combinations, doses, concomitant drugs and additional treatment exposure remain unread. |
Original intervention, comparator, stopping criteria, actual exposure and accompanying care |
Obtain the original arm-specific tables of drugs, prophylactic and treatment exposure, actual duration and accompanying care. |
| 4 |
Partly verified |
Full text not readStored summary read |
N04 · Comparative efficacyAre 196 randomized participants distinguished from 193 in the primary analysis and denominators 95/98?Required |
After 196 participants were randomized, the prespecified per-protocol primary analysis included 193 (95/98), excluding 3 canceled surgeries. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The summary lacks original arm-specific randomized counts, cancellations by arm and additional follow-up losses. No new totals, dropout rates or certification of an all-randomized ITT analysis are produced. |
Arm-specific randomization, canceled surgery, analysis and follow-up flow |
Obtain the original participant flow, exclusion reasons, arm-specific allocation and analysis counts, and missing-data tables. |
| 5 |
Partly verified |
Full text not readStored summary read |
N05 · Comparative efficacyAre the open-label design and infection adjudicators' roles distinguished?Required |
The original design was a single-center open-label noninferiority randomized trial. The record states that infectious-disease specialists and clinicians not involved in care adjudicated 90-day CDC-defined SSI. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Non-involvement in care is not newly certified as blinding to allocation. Details of allocation concealment, assessor blinding and analyst independence remain unread. |
Allocation, concealment, measurement, adjudicator and analyst procedures |
Obtain the original allocation, adjudication, blinding and analysis procedures. |
| 6 |
Partly verified |
Full text not readStored summary read |
N06 · Comparative efficacyWhat is the actual access status of registration, protocol and analysis-plan materials?Required |
The registration identifier in the original evidence list is NCT03305627. The preserved summary records a prespecified per-protocol primary analysis and a prespecified 10%p margin. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. No new URL was constructed from the registration identifier, and registration, full text and plans were not read. Details of the original primary/secondary exposure hierarchy and testing plan remain unread. |
Original registration, protocol, SAP, outcome hierarchy and amendment history |
Obtain the original registration, plans, analysis populations, hierarchy, amendments and multiplicity information. |
| 7 |
Partly verified |
Full text not readStored summary read |
N07 · Comparative efficacyWhat direct outcome is 90-day CDC-defined SSI?Required |
The selected question is noninferiority for CDC-defined surgical-site infection within 90 days. Infectious-disease specialists and clinicians not involved in care adjudicated the outcome. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The summary lacks detailed definitions and results for superficial, deep and organ-space categories, and visit schedules. Other infection or wound measures are not substituted. |
Infection definition, categories, ascertainment, time points and denominators |
Obtain the original CDC definitions, classification, ascertainment, results by time point and denominators. |
| 8 |
Partly verified |
Full text not readStored summary read |
N08 · Comparative efficacyAre arm-specific SSI events 8/95 and 12/98 and original percentages preserved?Required |
The original materials record 90-day SSI as 8/95 (8.4%) in the short arm versus 12/98 (12.2%) in the extended arm. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. People, repeated events, original denominators and all infections are not mixed. No new percentages, RR, event totals, P values or CI are calculated. |
Arm-specific events, people, denominators, original percentages and time window |
Obtain the original event tables, arm-specific denominators, repeated-infection records and analysis definitions. |
| 9 |
Partly verified |
Full text not readStored summary read |
N09 · Comparative efficacyAre the risk-difference direction and 90% CI preserved as originally recorded?Required |
The original SSI risk difference is −3.8%p (90% CI −11.1~3.4). |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. 90% is not changed to 95%. No new reverse-direction effect, risk ratio, test P value or adjusted model is produced. Details of the original risk-difference calculation remain unread. |
Risk difference of interest, arm order, CI level and original model |
Obtain the original comparison direction, risk-difference model, CI calculation and denominators. |
| 10 |
Partly verified |
Full text not readStored summary read |
N10 · Comparative efficacyAre the prespecified 10%p noninferiority margin and scope of the original conclusion distinguished?Required |
The original materials state that the prespecified 10%p noninferiority margin was met, with 90% CI −11.1~3.4. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. No new certification is made without reading the clinical margin rationale, original assumptions, α, test P value and plans. No new margin or examples of allowable events are produced. |
Margin, direction, rationale, prespecification, CI and plans |
Obtain the margin rationale, prespecification, testing and analysis plans, and original CI. |
| 11 |
Partly verified |
Full text not readStored summary read |
N11 · Comparative efficacyHas noninferiority been kept separate from superiority for reducing infection and exact equivalence?Required |
The original trial used a noninferiority design and records SSI risk difference −3.8%p and 90% CI −11.1~3.4. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The direction of the original percentages alone does not establish superiority for reducing infection or equivalence with exactly no difference. |
Original design, effect, interval, hypothesis and interpretation |
Link the original hypothesis, interval, margin and effect interpretation to the relevant question. |
| 12 |
Partly verified |
Full text not readStored summary read |
N12 · Comparative efficacyAre the per-protocol primary analysis and gaps in ITT and sensitivity analyses distinguished?Required |
The prespecified per-protocol primary analysis included 193 participants after excluding 3 canceled surgeries. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. This analysis is not converted into an ITT analysis of all 196 randomized participants. Details of ITT, sensitivity analyses, arm-specific cancellations, losses and original analysis mapping are unavailable. |
Original PP, ITT, cancellation, adherence, missingness and sensitivity-analysis definitions |
Obtain the original PP/ITT definitions, exclusions, adherence, missing-data assumptions, sensitivity analyses and original CI. |
| 13 |
Partly verified |
Full text not readStored summary read |
N13 · Comparative efficacyWhat are the follow-up, missingness and ascertainment limits within the original infection period?Required |
The original primary endpoint period is 90 days, and the SSI analysis denominators are 95/98. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. These denominators alone do not certify complete follow-up of all randomized participants, capture of infections at outside healthcare facilities or absence of missing information. |
90-day follow-up, visits, administrative/clinical ascertainment, missingness and denominators |
Obtain the original follow-up, infection ascertainment, missingness, denominators and handling of events outside the study center. |
| 14 |
Partly verified |
Full text not readStored summary read |
N14 · Comparative efficacyIs antibiotic duration the same outcome as SSI?Required |
In the same trial, antibiotic duration was 1 day (IQR1~1) versus 8 days (IQR7~10), with the original reduction of 7 days and 87.5%. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Reduced duration is not combined with SSI reduction, direct resistance reduction or safety as the same effect. Details of exposure-analysis denominators and hierarchy remain unread. |
Distinguishing exposure duration, endpoint, summary statistics and denominators |
Share the exposure outcome with the related question while linking it separately from the direct infection outcome. |
| 15 |
Partly verified |
Full text not readStored summary read |
N15 · Comparative efficacyAre clinical importance and original small-study limitations preserved without new assessment?Required |
The parent record describes objective 90-day SSI and a prespecified margin as strengths, and noninferiority, small size and exclusion of canceled surgery as limitations, preserving C56. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Unrecorded precision, the original parent verdict and axes are not repurposed as a new or subclaim score. No new sample-size, power or MCID calculations are made. |
Infection, margin, precision, sample size and original limitations |
Obtain the original sample-size assumptions, clinical margin rationale and precision information. |
| 16 |
Partly verified |
Full text not readStored summary read |
N16 · Comparative efficacyAre the two subclaims from the same trial kept separate from independent replications?Required |
One PAPRAC report records both 90-day SSI and antibiotic duration, so the two subclaim tables share the same trial and population. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Report entries, two questions, outcomes and time points are not added as new independent trials or participants. Final independent-study and total-participant counts remain unrecorded. |
Relationships among report, trial, shared participants, outcomes and related questions |
Link additional reports while preserving original identifiers and population and time-point relationships. |
| 17 |
Partly verified |
Full text not readStored summary read |
N17 · Comparative efficacyWhat is known about company and institutional funding, in-kind support, affiliations and analysis roles?Required |
The original summary records no reported external grant or company in-kind support, and sponsorship and conduct by Insel Gruppe AG and University Hospital Bern. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. No reported support is not converted into certification of no support or company involvement. Separate details of employee authors, external analysis, design and writing roles remain unread. |
Cash, products/in-kind support, author affiliations, external analysis and study roles |
Obtain the original support, in-kind, affiliation, analysis, design and writing disclosures separately. |
| 18 |
Partly verified |
Full text not readStored summary read |
N18 · Supplementary harm evidenceAre 90-day mortality counts, denominators and P distinguished from SSI?Required |
The original safety record gives 90-day all-cause mortality as 6/95 (6.3%) versus 5/98 (5.1%), P=.96. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. These results are not converted into antibiotic-related mortality, survival noninferiority or absence of rare harms. CI, causes, relatedness and hierarchy for the original mortality outcome remain unread, with no new calculation. |
Mortality definition, duration, arm-specific denominators, original events and testing |
Obtain original mortality, relatedness, denominator, plan, CI and follow-up materials. |
| 19 |
Partly verified |
Full text not readStored summary read |
N19 · Supplementary harm evidenceWhat do the infection-resolution statement and treatment and safety collection cover?Required |
The original safety record states that all infections resolved with appropriate treatment. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. This statement is not extended to mean no infections, systematic collection of all harms or no risk. Details of other infections, treatments, people/events and recovery timing remain unread. |
Infection types, treatment exposure, follow-up, recovery, relatedness and denominators |
Obtain original infection, treatment-exposure, treatment-success definition, follow-up, relatedness and denominator records. |
| 20 |
Unverified |
Full text not readStored summary read |
N20 · Supplementary harm evidenceDoes shorter antibiotic exposure directly demonstrate reduced harms?Required |
The original materials record shorter prophylactic antibiotic exposure, 90-day SSI and mortality; parent safety is Caution. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Shorter exposure alone does not newly establish reductions in adverse drug reactions, kidney injury, allergy or other harms. The summary lacks the relevant original outcomes, denominators and collection details. |
Drug harms, collection, exposure, arm-specific events and denominators |
Obtain original harm-collection records, arm-specific events/people, exposure, discontinuation, relatedness and duration. |
| 21 |
Unverified |
Full text not readStored summary read |
N21 · Supplementary harm evidenceAre resistance selection pressure, individual resistance, costs and other infections distinguished?Required |
The original review summary records both a possible reduction in resistance selection pressure and costs through less exposure, and the limitation that individual resistance emergence and costs were not directly tested. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Mechanistic or stewardship advantages are not converted into established direct reductions in resistance or costs or prevention of other infections. |
Direct outcomes, definitions and denominators for resistance, costs and infection types |
Obtain prespecified direct measurements, denominators, effects and follow-up for resistance, costs and other infections. |
| 22 |
Unverified |
Full text not readStored summary read |
N22 · Supplementary harm evidenceWhat application gaps remain for populations, surgery, drugs and resistance environments outside the single center?Required |
The parent counterview records that results cannot be directly applied to robotic surgery, other antibiotic combinations or different resistance environments. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. No individual antibiotic choice, duration, postoperative-care or treatment-substitution guidance is generated. Efficacy and safety outside the original study conditions are not newly certified. |
Direct comparisons in new populations, surgeries, drug combinations and settings |
Obtain direct effects/harms, denominators and follow-up for each new population, surgery, drug and setting. |
| 23 |
Partly verified |
Full text not readStored summary read |
N23 · Comparative efficacyDo gaps remain in durability beyond 90 days and independent replication?Required |
The currently designated preserved summary contains one PAPRAC report and 90-day SSI. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Duration, outcomes and related tables are not counted as replication trials or extended to long-term resistance, readmission, mortality or all infections. |
Long-term follow-up, new trials, populations, centers and independence relationships |
Obtain long-term direct outcomes, independent-report relationships and center-specific materials. |
| 24 |
Partly verified |
Full text not readStored summary read |
N24 · Comparative efficacyAre the preserved summary and external abstract, full text, registration and plans distinguished?Required |
The complete parent-verdict summary was read for production, linking the existing PubMed URL for Thurnheer et al. 2024, PMID39422911 and identifier NCT03305627. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. External abstract, full text, registration, protocol and SAP remain unread; no separate link test was performed. No new URL or DOI is constructed from identifiers. |
Bibliography, existing links, registration identifiers and material-specific access status |
Link individual original materials supplied by the user separately from their actual access status. |
| 25 |
Partly verified |
Full text not readStored summary read |
N25 · Comparative efficacyAre the reference date, Korean/English texts, corrections, empty values, candidate history and production state preserved?Supplementary |
2026-08-26, empty correction and deliberation values, Korean/English texts, parent C56, Caution and axes, and the subclaim C grade and note are preserved in their original form. |
Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Original statements, including the sample-size wording in the parent rationale, remain historical records without new correction or reassessment. Original review-pending and production-eligibility indicators are candidate history, not current review or completion. |
Distinguishing the complete preserved summary, selected verdict record, parent values, original languages and history |
Preserve original texts before linking additional user materials or decisions as separate events. |